title: Pathology consultation on warfarin pharmacogenetic testing.
authors.affiliation: VA Connecticut Healthcare System, West Haven, CT 06516, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Stack
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D006470:Hemorrhage / Q000139:chemically induced / Q000235:genetics / Q000517:prevention & control; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases